|
Evening all,
Unfortunately today's play (MRES) gapped up and after a
strong initial burst higher, it trended lower the rest of the day. I always warn my readers to be wary of gap ups, as it is something we simply cannot control.
It also appeared many traders stayed away on this Election Day, which showed as trading volume across the entire market was extremely light.
We
still think there is a good pullback opportunity however. We stand by
our analysis of MRES, and we are expecting news from the Company in the next few days which could
be a major catalyst for a surge higher.
But we want some more immediate gains so tonight I'll be diligently doing research on a potential Ebola related play and will bring you this later tonight or tomorrow morning.
Ebola plays are still hot right now so if you missed the boat on some early runners, hopefully we can play catch up tomorrow.
I'll be back soon, until then, enjoy your evening.
ShiznitStocks.com
_______________________________________________
Hello fellow investors / traders,
Every once in a while we find a true undiscovered company that we feel compelled to bring to the attention of our readers.
And after doing some extensive due diligence, we found a lot to like about tomorrow's play.
Let's take a closer look as to why Institute of BioMedical Research Corp (MRES) could be the market's darling in the coming days/weeks.
Let me start by saying, gains will be made in MRES. If you like investing and/or trading in companies that:
- have a long solid history of operations
- are generating revenues and net surpluses - right now
- have a strong balance sheet with a very healthy cash balance
- operate in a massively growing industry with real takeover / buyout potential
- a good capital structure with a very thin level 2
- a history of delivering excellent short term gains for shareholders/traders.
Then you must keep reading.
MRES has a very thin level 2. So thin that we think triple digit gains are a realistic possibility. And if you look at the six month chart, you will see that such gains have been a regular occurrence.
MRES is a revenue generating
company that reported a strong net income of $173k before tax in its
last quarter ended 30 June 2014.
MRES also has a strong cash flow with over $200k cash on their balance sheet.
We love real companies, doing real things that are already generating income. We especially love these companies when we are among the first to discover such companies.
MRES is everything we love about investing in undiscovered plays. As usual the Street has been way to slow to identify the potential in MRES.... Advantage us. Our ground floor entry awaits.
The Institute of BioMedical Research (MRES) is a biomedically ambitious
business venture whose activities extend from highly diversified
scientific research and sophisticated services (research and
development, quality control and standardization of pharmaceuticals,
cosmetics and food products) up to major long term biomedical and
environmental research projects, as well as the development of new
diagnostic technologies and innovative experimental medical treatments.
Regulatory certification of new drugs and biomedical products also
constitutes important business activities of the Institute. The
Institute is essential for the development of Montenegro within the
regional and European environment.
The new Institute was created on the strength of more than 22 years of
pertinent knowledge and experience that its founding company BioMedco
from Montreal, has acquired in a variety of academic, scientific,
technical and industrial sectors subject to the rigorous regulatory
requirements of the appropriate authorities of Canada and the United
States of America (USA).
The Company's vision is to be the first Neuro-pharmaceutical company to bring to market analytical
diagnostic products specifically designed to facilitate early diagnosis, and monitoring.
This will allow follow-up treatments, through a targeted therapeutic approach to
the major psycho-social environmental diseases related to the Neuro-psycho-endocrine
and immune systems.
In addition, MRES is planning the gradual development of the following professional activities:
- Quality Control of Pharmaceutical, Cosmetic and Food Products
- Environmental Analyses
- Research and Development of New Pharmaceutical & Biomedical Products
- Clinical Studies of New Drugs, Cosmetic and Biomedical Products
- Scientific Research
- Postgraduate Academic Education and Training
- Regulatory Evaluation & Certification of New Biomedical, Cosmetic and Food Products
- Public Health Regulatory System & its Institutional Structures Reorganization
- Experimental Medical Diagnostics and Treatments by its EMC
- Import & Export of Drugs, Cosmetic, Food and Biomedical Products and Equipments, as well as Laboratory Furniture and Devices
- "Virtual" Laboratory Program
- Editing and Publishing a Peer Review Scientific Journal "Annals of the Institute of Biomedical Research - Podgorica".
In addition, MRES offers a plethora of professional services
including medical expertise, quality control, regulatory, health care,
environmental, building decontamination as well as environmental
protection and management. You can read more about these services in
depth at http://www.institutebmr.com/category/services/
You can also read more about MRES, its history and its mission/objectives and its management on their website http://www.institutebmr.com
We urge you to continue your research on this
potential sleeping giant. It's not often we see companies such as MRES
that are general revenues and earnings NOW that have so much more
potential.
We expect strong gains to be had tomorrow and further into the future. But getting in early is an absolute must.
We are also hearing there could be news in the morning, so of course we will keep you up to date.
www.ShiznitStocks.com
Disclaimer
Never invest in any stock featured on our
site or emails unless you can afford to lose your entire investment. For full
disclaimer click here.
ShiznitStocks.com employees are not registered as an Investment Adviser in any
jurisdiction whatsoever. The disclaimer is to be read and fully understood
before using our site, or joining our email list. None of the materials or
advertisements herein constitute offers or solicitations to purchase or sell
securities of the companies profiled herein and any decision to invest in any
such company or other financial decisions should not be made based upon the
information provide herein. Instead ShiznitStocks.com strongly urges you
conduct a complete and independent investigation of the respective companies
and consideration of all pertinent risks. ShiznitStocks.com does not offer such
advice or analysis, and ShiznitStocks.com further urges you to consult your own
independent tax, business, financial and investment advisors. Investing in
micro-cap and growth securities is highly speculative and carries and extremely
high degree of risk. It is possible that an investor's investment may be lost
or impaired due to the speculative nature of the companies profiled. Any
statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals, assumptions or
future events or performance are not statements of historical fact may be
"forward looking statements". Forward looking statements are based on
expectations, estimates, and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through use of
words such as "projects", "foresee", "expects",
"will", "anticipates", "estimates",
"believes", "understands", or that by statements indicating
certain actions "may", "could", or "might" occur.
Understand there is no guarantee past performance will be indicative of future
results. In preparing this publication, ShiznitStocks.com has relied upon
information supplied by its customers, and press releases which it believes to
be reliable; however, such reliability cannot be guaranteed. Investors should
not rely on the information contained in this website. Rather, investors should
use the information contained in this website as a starting point for doing
additional independent research on the featured companies. The advertisements
in this website are believed to be reliable, however, ShiznitStocks.com and its
owners, affiliates, subsidiaries, officers, directors, representatives and
agents have not completed any due diligence or research on the companies advertised
herein and disclaim any liability as to the completeness or accuracy of the
information contained in any advertisement and for any omissions of materials
facts from such advertisement. ShiznitStocks.com is not responsible for any
claims made by the companies advertised herein. ShiznitStocks.com may receive
compensation and its employees and affiliates may own stock that they have
purchased in the open market either prior, during, or after the release of the
companies profile which is an inherent conflict of interest in
ShiznitStocks.com statements and opinions and such statements and opinions
cannot be considered independent. ShiznitStocks.com reserves the right to buy
and sell shares of the profiled company on the open market before, during or
after the release of the company profile. In such an event, ShiznitStocks.com
will not update its disclaimer to reflect any shares bought or sold on the open
market during the profile coverage. ShiznitStocks.com and its management may
benefit from any increase in the share price of the profiled companies and hold
the right to sell the shares bought at any given time including shortly after
the release of the companies profile. ShiznitStocks.com has
been compensated two thousand dollars via electronic transfer from a non-affiliated third party for the
profile of MRES. ShiznitStocks.com may on occasion accept compensation in
restricted or free-trading shares for it's marketing services of the company
being profiled, and the third party that might have compensated ShiznitStocks.com
may hold free-trading shares of the company being profiled and could very well
be selling shares of the companies stock at the same time the profile is being
disseminated to potential investors; this should be viewed as a definite
conflict of interest and as such, the reader should take this into
consideration. If ShiznitStocks.com ever accepts compensation in the form
of restricted or free trading shares of the company being profiled and decides
to sell these shares into the public market at any time before, during, or
after the release of the companies profile our disclaimer will be updated
accordingly reflecting the current position of those free trading shares
received as compensation for our services. |